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GENERAL CONSIDERATIONS
Athletes commonly use drugs and dietary supplements
because they hope to improve athletic performance. These
performance-enhancing substances include ergogenic and
thermogenic supplements, stimulants, anabolic steroids,
peptide hormones, and others. Despite aggressive marketing
and user testimonials, scientific studies assessing the benefits
and risks of any of these substances have not been conducted
(1–5). Clinical observations indicate some supplements may
have serious side effects including fatal adverse reactions (6–8).
Athletes should make informed decisions regarding the use of
drugs and dietary supplements with careful consideration of
what is known and unknown. Health care professionals should
ask about drug and dietary supplements and serve as an
educational resource for athletes and athletic organizations (9).
Many drugs and supplements are marketed to improve
exercise duration or physical strength, to shorten recovery time
from exertion, to reduce fat, or in other ways to improve
athletic performance (1–3,10–13). These substances include
anabolic-androgenic steroids and the more than 30 natural and
synthetic derivatives including tetrahydrogestrinone (THG).
Androstenedione, commonly referred to as “andro,” and dehy-
droepiandrosterone (DHEA) are available in oral form and are
sold as nutritional supplements. Stimulants include amphet-
amines, cocaine, dexadrine, ephedra, ritalin, beta-2 agonists,
and others (1–3,10–13). Peptide hormones and analogues,
such as recombinant erythropoietin (EPO), are used as a
pharmacologic alternative to “blood doping” or autotransfusion
(1–3,10–13). Human growth hormone (hCG), chorionic go-
nadotropin, pituitary and synthetic gonadotropins (LH), and
corticotropins (ACTH, tetracosactide) also are used because
they are believed to improve athletic performance (1–3,10–13).
Dietary supplements are products, other than tobacco,
containing vitamins, minerals, amino acids, herbs, or other
botanical dietary substances (1–3,10–13). Some substances
such as vitamins, minerals, bee pollen, caffeine, glycine,
carnitine, lecithin, brewer’s yeast, gelatin, creatine, protein
supplements, and others probably have minimal toxicity
when used in recommended doses. Based on serious con-
cerns regarding the safety of a popular energy drink with
taurine, caffeine, and glucuronolactone, multiple European
countries have banned its sale (10). Like most dietary
supplements this drink has not been assessed for efficacy or
toxicity in rigorous scientific studies (1–3,10–13).
Other banned drugs that are not considered performance-
enhancing would come under the designation of recreational
drugs (1–5,13). These include alcohol, cannaboids, seda-
tives, narcotics, LSD, and others that have the potential to
impair cognitive and physical function and are prohibited
(1–3,12,13). The dietary supplement ephedra (ma huang) is
associated with life-threatening toxicity and death resulting
on a ban of its sale by the Food and Drug Administration
(6–8). Inadequate labeling and insufficient quality control
in the production of many nutritional supplements are also
reasons to recommend that athletes not take dietary supple-
ments. Contamination or poor labeling of nutritional sup-
plements are not regarded as adequate defenses by athletic
governing bodies. Recognizing that there may be excep-
tional circumstances where an athlete will require an oth-
erwise prohibited substance for medical purposes, formal
therapeutic exemption mechanisms are available with prior
consideration and approval (11–13).
Athletic governing bodies should provide comprehensive
lists of prohibited drugs and dietary supplements (1,11–13).
They should develop a rigorous approach to prevent
performance-enhancing and recreational drug and dietary
supplement use. The crucial elements of any program
should include education, counseling, treatment, detection,
and enforcement. Governing athletic bodies should use all
available resources to enhance, supplement, and coordinate
existing efforts to educate athletes and reinforce the ethical
principles inherent in athletic participation. Without such
oversight, the integrity of athletics is threatened. Ultimately,
athletes must accept responsibility for the decisions they
make regarding the usage of drugs and performance-
enhancing substances.
Athletes taking or considering the use of such substances
should be aware that the safety and efficacy of supplements
used for improving athletic performance have not been
addressed in systematic scientific studies. Trainers, exercise
physiologists, sports nutritionists, athletic governing bodies,
or medical organizations should discourage the use of
dietary supplements by athletes. Serious side effects may
result from the use of these substances, including cardiac
hypertrophy, myocyte necrosis, myocarditis, fibrosis, coro-
nary thrombosis, and sudden death (even at recommended
dosing) (2,3,6–8,10).
Recommendation:
1. Athletes should have their nutritional needs met through
a healthy, balanced diet without dietary supplements.
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GENERAL CONSIDERATIONS OF
CARDIAC ARREST RISK AMONG ATHLETES
The incidence of out-of-hospital cardiac arrest among the
general population of adults is 1 to 2 deaths per 1,000
subjects per year; a figure that represents 50% of all
cardiovascular deaths (1). For the adolescent and young
adult subgroups, the estimated incidence is 1 per 100,000
per year or less. Available data suggest that among the
younger population, competitive athletes account for a
disproportionately higher-risk subset, compared to the gen-
eral population in a comparable age group (2–4). In
addition, among the adult population performing condi-
tioning activities in health clubs, the probability of cardiac
arrest during exertion appears higher than the expected rate
for comparable groups generally, especially among persons
who exercise despite being habitually sedentary (5).
Within the subgroup of the population age 35 years and
older, coronary heart disease accounts for approximately
80% of all sudden cardiac deaths (SCDs), with the cardio-
myopathies accounting for another 10% to 15%. In the
younger age groups, hypertrophic cardiomyopathy, anoma-
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